Power Law company profile

Intersect ENT

Biotech & Life Sciences · Menlo Park, United States · Founded 2003 · IPO 2014 Unicorn

Intersect ENT - Propel Mometasone Furoate Implant

Valuation

$813M

Market cap · 2026

Revenue

$160M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

2 investors on Intersect ENT's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 2 investors entered at this stage

Kleiner Perkins

U.S. Venture Partners

Global footprint

Where Intersect ENT has talent and traffic

Workforce by country

🇺🇸 United States · Menlo Park HQ

Book a demo for the full country breakdown

Web traffic by country

70 monthly visits
across markets

🇺🇸 United States142.9%

Top 1 markets shown

Patent intelligence

$70M patent portfolio · 39 active families

Estimated portfolio value

$70M

8.6% of market cap · 13.2× smaller than top peer Globus Medical ($930M)

39 active patent families

Where Intersect ENT innovates Medical instrumentsMedical physicsBiomedical engineeringGeneral surgeryPharmaceutical drug

Where Intersect ENT concentrates vs peers

Each axis is a top-10 topic across Intersect ENT and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Intersect ENT

An AI-synthesized read of the highest-engagement posts about Intersect ENT on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Intersect ENT on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles